Physician profile
Marconi Abreu
NPI 1144428319
$13,694.96
in general payments reported to CMS, 2019-2025
10 companies · $3,487 in 2025
The $3,487 reported for 2025 was more than what 85% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,870 · 2021: $6,456 · 2022: $352 · 2023: $105 · 2024: $425 · 2025: $3,487.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,825 · Food and Beverage: $1,042 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,825.00 |
| Food and Beverage | $1,042.19 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $9,807.85 | 2019-2025 | |
| Novo Nordisk INC | $2,235.20 | 2019-2025 | Ozempic |
| Abbott Laboratories | $447.35 | 2021-2024 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $335.63 | 2019 | |
| Dexcom, INC. | $217.98 | 2019-2023 | Dexcom G7 Gss (161) |
| Mannkind Corporation | $174.62 | 2019 | |
| Tandem Diabetes Care, INC. | $140.22 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $124.72 | 2022 | |
| Sequel Med Tech, LLC | $111.42 | 2025 | Twiist |
| Insulet Corporation | $99.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marconi Abreu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.